#Pfizer has claimed its first #regulatoryapproval for a #GLP1 agonist in #obesity, getting a green light in #China for ecnoglutide, a once-weekly #injectable drug licensed from Hangzhou-based #SciwindBiosciences in February.

buff.ly/wJeVK7h